Jim Price shares a whitepaper he co-authored with Abby Coleman, and Haley Teves on the 340B-eligible health system.  This paper explores how a 340B-eligible health system can leverage its control of its own health plan to lower its net drug benefit costs by increasing the compliant-usage of 340B (which generates margin by the Covered Entity hospital(s)). This requires integrating data from both the health plan’s PBM and the Covered Entity’s 340B vendor, and then analyzing from both a “population health”…